46 results about "Motor symptoms" patented technology

A state of progression in an individual of a disease or treatment having motion symptoms is determined. A time series of accelerometer data is obtained from an accelerometer worn on an extremity of the person, over an extended period during everyday activities of the person. The accelerometer data is processed to produce a plurality of measures of kinetic state of the individual at a respective plurality of times throughout the extended period, each measure of kinetic state comprising at least one of: a measure for bradykinesia, and a measure for dyskinesia. A measure of dispersion of the measures of kinetic state is determined. An output is generated, indicating that motion symptoms are at an initial stage if the measure of dispersion is less than a threshold, or indicating that motion symptoms are at an advanced stage if the measure of dispersion is greater than the threshold.

A gait disorder support apparatus and gait disorder support method capable of detecting an onset sign of a gait disorder associated with motor symptoms in advance and performing motion assist are proposed. The onset sign of the gait disorder associated with the motor symptoms of a wearer is detected based on the correlation between a gait cycle and a reduction ratio of the gait cycle as compared to immediately preceding gait; and when the onset sign of the gait disorder is detected, a drive unit is controlled so that the drive unit applies assist power to a knee joint of the wearer; and on the other hand, when the onset sign of the gait disorder is not detected, the drive unit is controlled so that driving torque by the drive unit does not hinder the wearer's gait motion.

A method for treating a symptom of a neurodegenerative condition. The method includes topically administering a composition that contains a sex steroid or a cannabinoid or a mixture of both to the forehead, to an area of the outer ear of the subject not including the ear canal, or to both of these anatomical locations. The symptom treatable by the method is a motor symptom or a non-motor symptom.

This invention refers to a device that reduces and counteracts human motor symptoms (tremor in the upper limbs, muscular stiffness, bradykinesia or slowness in movements, postural disruptions, Parkinsonian walking and freezing in the walking) caused by Parkinson's disease. The device produces vibration by means of a micro-motor that can be modulated in time, speed and power. A laser diode generates a light that is projected in the ground in the form of a horizontal line, a Bluetooth module communicates this device with different intelligent electronic devices and with applications. These components are powered by a rechargeable handheld power source. The components are powered by a rechargeable handheld electric energy source.

The invention relates to a Parkinson's disease biomarker and application thereof, and belongs to the technical field of medical diagnosis. The biomarker comprises the methylation degree of at least one gene locus in the genes of GPR183, WDR46, PFDN6, SGCE, PEG10, EMX2OS, NFATC4, GJB1, IGF1R, UBAC2, ICA1L, ACRC, PAX6, ALX4, HIST1H4C, HSPA1L, LOC645323, BCYRN1, IGF2BP3, ZNF808, OTUD6A, NELL2, TAF1, EMX2, ARHGAP6, and RALYL. Only the methylation site of the Parkinson's disease biomarker needs to be directionally detected, the experimental method and the judgment method can be standardized, and misdiagnosis caused by human subjective deviation is avoided. Moreover, the Parkinson's disease biomarker can be detected from biological samples such as peripheral blood before the motor symptom of a patient attacks, so that the aim of early diagnosis can be fulfilled.

The invention provides a Parkinson's disease non-motor symptom monitoring platform and application thereof, and belongs to the technical field of online medical treatment. The monitoring platform comprises a patient module, a doctor module and an information processing module. A patient completes a Parkinson's disease non-motor symptom visualization scale on time to assist a doctor in diagnosis and disease course monitoring, and information interaction is realized in the form of an app, a web page or a WeChat applet. The monitoring platform does not occupy the time of clinical communication, and a patient can complete the evaluation on the terminal by himself/herself. When a doctor sees a doctor every time, by calling patient information and an analysis result, the burden rating of the non-motor symptoms can be quantified, the current situation and progress of the non-motor symptoms of the patient can be quickly and accurately mastered, and diagnosis can be timely and accurately carried out.

The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when effectiveness of standard medications wear off or side effects become problematic, as seen in Parkinson's disease, other disorders treated with dopaminergic agents, and other conditions associated with motor problems, such as aging or stroke. The treatment also may include disease-modifying effects, neuroprotection of, or neurorescue effects on neuronal cells in patients with Parkinson's disease and other neurodegenerative disorders. In particular, the invention relates to method of administering pharmaceutical compositions comprising effective amounts of tapentadol or a pharmaceutically acceptable salt or derivative thereof or, in other embodiments, stavudine or nabumetone, or a derivative thereof, for treating symptoms associated with Parkinson's disease, either as individual active agents, in combination with each other, or in combination with agents known to treat Parkinson's disease, such as the dopaminergic agent levodopa. The invention also relates to methods of preparing pharmaceutical compositions comprising effective amounts of tapentadol, stavudine, or nabumetone, or a derivative thereof, or further in combination with a dopaminergic agent, or derivative thereof, as well as to methods of using the pharmaceutical compositions in treating Parkinson's disease, related disorders, other conditions treated with dopaminergic agents, and other conditions with gait problems, for example by oral administration of the compositions.

The invention discloses a probiotic composition for treating rapid eye movement sleep behavior disorder (RBD) in patients with Parkinson disease (PD). The composition is prepared from bacillus licheniformis, bifidobacterium longum, lactobacillus acidophilus, enterococcus faecalis and pharmaceutically acceptable auxiliary materials, wherein the number of live bacteria of the bacillus licheniformisis not less than 10.0x10<8> CFU/g; the number of live bacteria of the bifidobacterium longum is not less than 4.0x10<8> CFU/g; the number of live bacteria of the lactobacillus acidophilus is not lessthan 1.0x10<8> CFU/g; and the number of live bacteria of the enterococcus faecalis is not less than 0.5x10<8> CFU/g. In the probiotic composition, the components have a synergistic effect, the RBD symptom in the PD patients can be effectively treated and improved, and the treatment effect is good in continuity and excellent in stability; the composition can effectively improve the motor symptom ofthe PD patients while having a treatment effect on the RBD symptom of the PD patients, and solves the problem that current drugs cannot treat the motor symptom and non-motor symptoms of the PD patients at the same time; and the composition can effectively reduce the dosage of levodopa in the PD patients and prevent the patients from generating resistance to levodopa prematurely, and has a betterprotection effect on the patients.

The invention discloses an application of rotigotine microspheres in preparation of a medicine for treating inflammatory pain. Rotigotine is a dopamine receptor agonist, and the long-acting sustained-release microsphere can obviously prolong the recession incubation period of the rat posterior claw to thermal stimulation and mechanical stimulation after carrageenan inflammation; the rotigotine microsphere is capable of inhibiting the expression of inflammatory tissue PGE2 and proving that the rotigotine microsphere has an analgesic effect on inflammatory pain, can be used for treating exercisesymptoms of Parkinson's disease and treating the pain of the Parkinson's disease or accompanied diseases, and the analgesic effect can be maintained for 4 days after one-time administration.

The invention relates to the field of new application of medicines, in particular to application of anisodine hydrobromide in treatment of Parkinson's disease. The Parkinson's disease (PD) is a common neurodegenerative disease, the motion symptoms of the PD are acute or static tremor, motion retardation, myotonia, posture balance disorder and the like, at present, the Parkinson's disease is clinically treated mainly by drugs such as levodopa and dopamine, but drug resistance appears along with the prolonging of medication time, and the Parkinson's disease is caused by the drug resistance. The treatment effect and rehabilitation are directly influenced. The anisodine hydrobromide can well improve the treatment effect and shorten the treatment time, so that the influence of drug resistance is reduced.

The invention discloses a method for treatment of epilepsy-associated motor symptom and/or cognitive impairment, by co-administering clavulanic acid and valproic acid to an epilepsy subject in need thereof. Clavulanic acid can be administrated in a dosage of 0.016-10 mg/kg/day, while valproic acid can be administrated in a dosage of 0.8-30 mg/kg/day. Moreover, clavulanic acid and valproic acid can be administrated concurrently, sequentially, separately, continuously or intermittently. In addition, clavulanic acid, as well as valproic acid, can be administrated orally or parenterally.

The invention discloses a pharmaceutical composition, including clavulanic acid and valproic acid, for treatment of epilepsy seizure and/or for treatment of epilepsy-associated motor symptom and cognitive impairment. The invention also discloses a method treatment of epilepsy seizure and/or for treatment of epilepsy-associated motor symptom and cognitive impairment, by co-administering clavulanic acid and valproic acid to a subject in need thereof.